Endoglin in the spotlight to treat cáncer

Description

A spotlight has been shone on endoglin in recent years due to that fact of its potential to serve as both a reliable disease biomarker and a therapeutic target. Indeed, endoglin has now been assigned many roles in both physiological and pathological processes. From a molecular point of view, endoglin mainly acts as a co-receptor in the canonical TGFβ pathway, but also it may be shed and released from the membrane, giving rise to the soluble form, which also plays important roles in cell signaling. In cancer, in particular, endoglin may contribute to either an oncogenic or a non-oncogenic phenotype depending on the cell context. The fact that endoglin is expressed by neoplastic and non-neoplastic cells within the tumor microenvironment suggests new possibilities for targeted therapies. Here, we aimed to review and discuss the many roles played by endoglin in different tumor types, as well as the strong evidence provided by pre-clinical and clinical studies that supports the therapeutic targeting of endoglin as a novel clinical strategy.

Abstract

H.P. Departamento de Defensa de EE. UU. W81XWH-16-1-0131

Abstract

Fundación Proyecto Neurofibromatosis. T.G.M.FPU (Ministerio de Ciencia, Innovación y Universidades, Gobierno de España). Retos-Colaboración RTC-2014-2102-1 y PI17-000464 de MINECO-FEDER

Additional details